S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
Are These Consumer Staples Too Cheap for Investors To Ignore?
Is Gold Really Boring? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
Is Gold Really Boring? (Ad)
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
3 Reasons This Tech Giant Is Going Back To Highs
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
Are These Consumer Staples Too Cheap for Investors To Ignore?
Is Gold Really Boring? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
Is Gold Really Boring? (Ad)
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
3 Reasons This Tech Giant Is Going Back To Highs
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
Are These Consumer Staples Too Cheap for Investors To Ignore?
Is Gold Really Boring? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
Is Gold Really Boring? (Ad)
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
3 Reasons This Tech Giant Is Going Back To Highs
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
Are These Consumer Staples Too Cheap for Investors To Ignore?
Is Gold Really Boring? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
Is Gold Really Boring? (Ad)
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
3 Reasons This Tech Giant Is Going Back To Highs
NASDAQ:PROC

Procaps Group (PROC) Stock Forecast, Price & News

$3.70
0.00 (0.00%)
(As of 09/20/2023 ET)
Compare
Today's Range
$3.70
$3.70
50-Day Range
$3.50
$4.24
52-Week Range
$3.50
$7.75
Volume
170 shs
Average Volume
5,117 shs
Market Capitalization
$417.43 million
P/E Ratio
5.61
Dividend Yield
N/A
Price Target
$4.50

Procaps Group MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
21.6% Upside
$4.50 Price Target
Short Interest
Healthy
0.16% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.43 out of 5 stars

Medical Sector

845th out of 961 stocks

Pharmaceutical Preparations Industry

409th out of 455 stocks


PROC stock logo

About Procaps Group (NASDAQ:PROC) Stock

Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.

PROC Price History

PROC Stock News Headlines

Procaps Group, S.A. (PROC) Q2 Earnings Surpass Estimates
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
-20%
Procaps Group Reports Second Quarter 2023 Results
PNC - The PNC Financial Services Group, Inc.
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
Softgel Capsules Market Demand by 2030
Procaps Group S.A.
Procaps Announces Key Changes to the Board of Directors
See More Headlines
Receive PROC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Procaps Group and its competitors with MarketBeat's FREE daily newsletter.

PROC Company Calendar

Today
9/21/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PROC
Fax
N/A
Employees
5,500
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.50
High Stock Price Forecast
$4.50
Low Stock Price Forecast
$4.50
Forecasted Upside/Downside
+21.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$42.54 million
Pretax Margin
21.35%

Debt

Sales & Book Value

Annual Sales
$409.92 million
Cash Flow
$0.53 per share
Book Value
($0.02) per share

Miscellaneous

Free Float
90,369,000
Market Cap
$417.43 million
Optionable
Not Optionable
Beta
0.05
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Ruben Minski (Age 71)
    Founder, CEO & Chairman
  • Mr. Patricio Vargas Munoz (Age 50)
    Global Chief Financial Officer
  • Dr. Camilo Camacho (Age 49)
    Chief Operations Officer
  • Ms. Melissa Angelini
    Investor Relations Director
  • Ms. Marcela Carvajalino Pagano (Age 56)
    Vice-Pres of Corp. & Legal Affairs
  • Mr. Luis Alberto Palacios Aragon (Age 59)
    Vice-Pres of International Marketing and R&D
  • Mr. Mauricio Castaneda Caballero (Age 46)
    Vice-Pres of HR
  • Mr. Carlos Piocuda Russo (Age 38)
    Head of Optimization of Corp. Value & Corp. VP of Fin.













PROC Stock - Frequently Asked Questions

Should I buy or sell Procaps Group stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Procaps Group in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" PROC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PROC, but not buy additional shares or sell existing shares.
View PROC analyst ratings
or view top-rated stocks.

What is Procaps Group's stock price forecast for 2023?

1 Wall Street research analysts have issued 1 year price objectives for Procaps Group's shares. Their PROC share price forecasts range from $4.50 to $4.50. On average, they anticipate the company's share price to reach $4.50 in the next year. This suggests a possible upside of 21.6% from the stock's current price.
View analysts price targets for PROC
or view top-rated stocks among Wall Street analysts.

How have PROC shares performed in 2023?

Procaps Group's stock was trading at $5.25 on January 1st, 2023. Since then, PROC shares have decreased by 29.5% and is now trading at $3.70.
View the best growth stocks for 2023 here
.

When is Procaps Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our PROC earnings forecast
.

What is Procaps Group's stock symbol?

Procaps Group trades on the NASDAQ under the ticker symbol "PROC."

Who are Procaps Group's major shareholders?

Procaps Group's stock is owned by many different retail and institutional investors. Top institutional shareholders include Activest Wealth Management (0.01%).

How do I buy shares of Procaps Group?

Shares of PROC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Procaps Group's stock price today?

One share of PROC stock can currently be purchased for approximately $3.70.

How much money does Procaps Group make?

Procaps Group (NASDAQ:PROC) has a market capitalization of $417.43 million and generates $409.92 million in revenue each year. The company earns $42.54 million in net income (profit) each year or $0.66 on an earnings per share basis.

How many employees does Procaps Group have?

The company employs 5,500 workers across the globe.

How can I contact Procaps Group?

Procaps Group's mailing address is 1425 BRICKELL AVE #57B, MIAMI FL, 33131. The official website for the company is unionacquisitiongroup.com. The company can be reached via phone at 356 7995-6138 or via email at latn@mzgroup.us.

This page (NASDAQ:PROC) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -